KBC Securities - Tigenix NV (TGXSF) KBC Securities Morning Note 13-6-2018 TIG BB

Report

KBC Securities

Lenny Van Steenhuyse ...

Ruben Devos

KBC Securities Morning Note 13-6-2018 TIG BB

Tigenix: CEO steps back
Telecom: De Croo aims to keep spectrum free for 4th MNO

13/06/2018 6 EN

Underlying

Tigenix NV

TiGenix develops and commercializes cell therapy products. Co.'s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. Co.'s main product, ChondroCelect, is a cell-based product that is used for cartilage repair in the knee. Co.'s is also involved in developing Cx601, which is in Phase III clinical trial for the treatment of complex perianal fistulas in patients suffering from Crohn's disease; Cx611, which has completed a Phase IIa clinical trial for the treatment of rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of autoimmune diseases.

See profile

BE0003864817 Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Lenny Van Steenhuyse

Ruben Devos

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.75

November 25, 2019 November 25, 2019 14 EN

GlobeNewsWire

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period TiGenix becomes a wholly owned subsidiary of Takeda Ordinary Shares have been delisted from Euronext Brussels The ADSs have been delisted from Nasdaq and TiGenix plans to terminate the ADS Facility and suspend its U.S. reporting obligations Osaka, Japan and Leuven, Belgium, July 31, 2018, 8 a.m. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix N...

July 31, 2018 July 31, 2018 1 EN

Morning Notes : PROX BB, WDP BB

: PROX BB, WDP BB

April 19, 2024 April 19, 2024 1 EN

Wim Lewi

Wim Lewi

Warehouses De Pauw 1Q24 Results, pro-active hedging lowers cost of debt

GRI 1Q24 came slightly above our expectation, but the EPRA EPS was bang in line. A remarkable metric is the decline in Cost of Debt from 1.9% to 1.7% against a backdrop of rising interest rates. WDP “over-hedged” its debt in anticipation of its investment program and raised capital. WDP repeated the FY24 EPRA EPS guidance of 1.47, slightly above our 1.46 expectation. The 5% expected yoy growth is impressive as WDP issued 5.9% new shares last November. Expired contracts (100k Sqm GLA) were reviewed with 15% uplift (under-rented). WDP recently presented its “Blend27” strategy with a guidance of...

April 19, 2024 April 19, 2024 1 EN

Guy Sips ... (+5)

Guy Sips
Hilde Van Boxstael
Michiel Declercq
Thibault Leneeuw
Wim Lewi

Morning Notes : GREEN BB, SIP BB, AZE BB, DEME BB

: GREEN BB, SIP BB, AZE BB, DEME BB

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN